Bifogade filer
PDF
Kurs
+3,11%
Likviditet
1,41 MSEK
Kalender
| Est. tid* | ||
| 2026-08-20 | N/A | Årsstämma |
| 2026-05-08 | 07:00 | Bokslutskommuniké 2026 |
| 2026-02-03 | - | Extra Bolagsstämma 2026 |
| 2026-02-03 | - | Kvartalsrapport 2026-Q3 |
| 2025-11-05 | - | Kvartalsrapport 2026-Q2 |
| 2025-08-22 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2025-08-21 | - | Årsstämma |
| 2025-08-08 | - | Kvartalsrapport 2026-Q1 |
| 2025-05-08 | - | Bokslutskommuniké 2025 |
| 2025-02-05 | - | Kvartalsrapport 2025-Q3 |
| 2024-11-06 | - | Kvartalsrapport 2025-Q2 |
| 2024-08-20 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2024-08-19 | - | Årsstämma |
| 2024-08-08 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-14 | - | Bokslutskommuniké 2024 |
| 2024-02-14 | - | Kvartalsrapport 2024-Q3 |
| 2023-11-17 | - | Kvartalsrapport 2024-Q2 |
| 2023-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2023-08-17 | - | Årsstämma |
| 2023-08-16 | - | Kvartalsrapport 2024-Q1 |
| 2023-05-11 | - | Bokslutskommuniké 2023 |
| 2023-02-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-02-13 | - | Kvartalsrapport 2023-Q3 |
| 2022-11-11 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-26 | - | Extra Bolagsstämma 2022 |
| 2022-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2022-08-17 | - | Årsstämma |
| 2022-08-16 | - | Kvartalsrapport 2023-Q1 |
| 2022-05-13 | - | Bokslutskommuniké 2022 |
| 2022-02-16 | - | Kvartalsrapport 2022-Q3 |
| 2021-11-11 | - | Kvartalsrapport 2022-Q2 |
| 2021-08-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2021-08-18 | - | Årsstämma |
| 2021-08-18 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-06 | - | Bokslutskommuniké 2021 |
| 2021-02-18 | - | Kvartalsrapport 2021-Q3 |
| 2020-11-06 | - | Kvartalsrapport 2021-Q2 |
| 2020-08-28 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2020-08-27 | - | Årsstämma |
| 2020-08-27 | - | Kvartalsrapport 2021-Q1 |
| 2020-05-04 | - | Bokslutskommuniké 2020 |
| 2020-02-05 | - | Kvartalsrapport 2020-Q3 |
| 2019-11-11 | - | Kvartalsrapport 2020-Q2 |
| 2019-08-23 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2019-08-22 | - | Årsstämma |
| 2019-08-22 | - | Kvartalsrapport 2020-Q1 |
| 2018-08-22 | - | Årsstämma |
| 2018-05-24 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2018-05-23 | - | Bokslutskommuniké 2018 |
| 2017-10-24 | - | Kvartalsrapport 2018-Q3 |
| 2017-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2017-05-16 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2017-05-15 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2017-02-08 | - | Bokslutskommuniké 2017 |
| 2016-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2016-08-09 | - | Kvartalsrapport 2017-Q2 |
| 2016-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2016-05-13 | - | Årsstämma |
| 2016-05-13 | - | Kvartalsrapport 2017-Q1 |
| 2016-02-20 | - | Bokslutskommuniké 2016 |
| 2016-02-16 | - | Bokslutskommuniké 2016 |
| 2015-11-11 | - | Kvartalsrapport 2016-Q3 |
| 2015-10-09 | - | Extra Bolagsstämma 2016 |
| 2015-08-05 | - | Kvartalsrapport 2016-Q2 |
| 2015-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2015-05-18 | - | Årsstämma |
| 2015-05-18 | - | Kvartalsrapport 2016-Q1 |
| 2015-02-06 | - | Bokslutskommuniké 2015 |
| 2014-11-10 | - | Kvartalsrapport 2015-Q3 |
| 2014-08-13 | - | Extra Bolagsstämma 2015 |
| 2014-08-11 | - | Kvartalsrapport 2015-Q2 |
| 2014-05-13 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
| 2014-05-12 | - | Årsstämma |
| 2014-05-12 | - | Kvartalsrapport 2015-Q1 |
| 2014-02-07 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco S.p.A.. The launch of Mellozzan® in Italy is expected in the end of fiscal year 2026/27 or early 2027/28.
Italy will be the second greenfield market for Mellozzan, after Germany, where EQL, with the help of Italfarmaco's local expertise and infrastructure, will build the brand and generate prescriptions. The response from doctors and patients in Germany has been very good and the EQL hopes for an equally positive response in Italy.
About Mellozzan®
Mellozzan® contains the sleep hormone melatonin and is indicated for children with ADHD and suffering from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
About Italfarmaco
Italfarmaco SpA is one of the most successful pharmaceutical companies in Italy with a group turnover of almost 1,1 billion euros in 2024 and extensive sales and marketing resources in a number of European countries.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com